Recursion Pharmaceuticals Stock Options Expiring on 24th of January
RXRX Stock | USD 6.32 0.42 6.23% |
Recursion Pharmaceuticals' latest option contracts expiring on January 24th 2025 are carrying combined implied volatility of 2.78 with a put-to-call open interest ratio of 0.17 over 38 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on January 24th 2025. The total put volume is at 223, with calls trading at the volume of 786. This yields a 0.28 put-to-call volume ratio.
Open Interest Against January 24th 2025 Option Contracts
Recursion Pharmaceuticals option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in Recursion Pharmaceuticals' lending market. For example, when Recursion Pharmaceuticals' puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on Recursion Pharmaceuticals, he or she must hedge the risk by shorting Recursion Pharmaceuticals stock over its option's life.
2025-01-24
The chart above shows Recursion Pharmaceuticals' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Recursion Pharmaceuticals' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Recursion Pharmaceuticals' option, there is no secondary market available for investors to trade.
Recursion Pharmaceuticals Maximum Pain Price Across 2025-01-24 Option Contracts
Max pain occurs when Recursion Pharmaceuticals' market makers reach a net positive position across all Recursion Pharmaceuticals' options at a strike price where option holders stand to lose the most money. By contrast, Recursion Pharmaceuticals' option sellers may reap the most after selling more options than buying, causing them to expire worthless.
Recursion Pharmaceuticals In The Money Call Balance
When Recursion Pharmaceuticals' strike price is surpassing the current stock price, the option contract against Recursion Pharmaceuticals stock is said to be in the money. When it comes to buying Recursion Pharmaceuticals' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Recursion Pharmaceuticals are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Recursion Current Options Market Mood
Recursion Pharmaceuticals' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Recursion Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Recursion Pharmaceuticals' options investors are not very successful. Recursion Pharmaceuticals' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Recursion contract
Base on the Rule 16, the options market is currently suggesting that Recursion Pharmaceuticals will have an average daily up or down price movement of about 0.17% per day over the life of the 2025-01-24 option contract. With Recursion Pharmaceuticals trading at USD 6.32, that is roughly USD 0.011. If you think that the market is fully incorporating Recursion Pharmaceuticals' daily price movement you should consider buying Recursion Pharmaceuticals options at the current volatility level of 2.78%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Recursion |
Recursion Pharmaceuticals Option Chain
When Recursion Pharmaceuticals' strike price is surpassing the current stock price, the option contract against Recursion Pharmaceuticals stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Recursion Pharmaceuticals' option chain is a display of a range of information that helps investors for ways to trade options on Recursion. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Recursion. It also shows strike prices and maturity days for a Recursion Pharmaceuticals against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. Open Int | Strike Price | Current Spread | Last Price | |||
Call | RXRX250124C00002000 | 2 | 2.0 | 3.0 - 7.0 | 4.8 | In |
Call | RXRX250124C00005500 | 2 | 5.5 | 0.85 - 2.2 | 1.05 | In |
Call | RXRX250124C00005000 | 16 | 5.0 | 1.5 - 2.1 | 2.51 | In |
Call | RXRX250124C00004500 | 2 | 4.5 | 1.8 - 4.9 | 3.45 | In |
Call | RXRX250124C00007500 | 66 | 7.5 | 0.15 - 0.2 | 0.15 | Out |
Call | RXRX250124C00007000 | 1025 | 7.0 | 0.3 - 0.4 | 0.4 | Out |
Call | RXRX250124C00006500 | 15 | 6.5 | 0.5 - 0.65 | 0.5 | In |
Call | RXRX250124C00006000 | 133 | 6.0 | 0.85 - 1.0 | 1.0 | In |
Call | RXRX250124C00009000 | 328 | 9.0 | 0.0 - 0.1 | 0.06 | Out |
Call | RXRX250124C00008500 | 147 | 8.5 | 0.05 - 0.1 | 0.09 | Out |
Call | RXRX250124C00008000 | 1753 | 8.0 | 0.0 - 0.15 | 0.1 | Out |
Call | RXRX250124C00010000 | 614 | 10.0 | 0.0 - 0.05 | 0.05 | Out |
Call | RXRX250124C00012000 | 16 | 12.0 | 0.0 - 0.5 | 0.1 | Out |
Call | RXRX250124C00011500 | 0 | 11.5 | 0.0 - 4.8 | 4.8 | |
Call | RXRX250124C00011000 | 373 | 11.0 | 0.0 - 0.05 | 0.05 | Out |
Call | RXRX250124C00010500 | 15 | 10.5 | 0.0 - 1.0 | 0.13 | Out |
Call | RXRX250124C00014000 | 0 | 14.0 | 0.0 - 0.5 | 0.5 | |
Call | RXRX250124C00013500 | 0 | 13.5 | 0.0 - 0.5 | 0.5 | |
Call | RXRX250124C00013000 | 0 | 13.0 | 0.0 - 0.1 | 0.05 | |
Call | RXRX250124C00012500 | 0 | 12.5 | 0.0 - 0.5 | 0.5 | |
Call | RXRX250124C00015000 | 0 | 15.0 | 0.0 - 0.5 | 0.05 | |
Put | RXRX250124P00005000 | 56 | 5.0 | 0.0 - 0.05 | 0.03 | Out |
Put | RXRX250124P00006500 | 70 | 6.5 | 0.3 - 0.4 | 0.4 | Out |
Put | RXRX250124P00006000 | 43 | 6.0 | 0.15 - 0.25 | 0.23 | Out |
Put | RXRX250124P00008000 | 8 | 8.0 | 1.0 - 2.2 | 1.65 | In |
Put | RXRX250124P00007500 | 17 | 7.5 | 0.75 - 1.45 | 0.95 | In |
Put | RXRX250124P00007000 | 558 | 7.0 | 0.55 - 0.65 | 0.64 | In |
Put | RXRX250124P00009000 | 9 | 9.0 | 1.9 - 2.7 | 2.8 | In |
Put | RXRX250124P00010000 | 0 | 10.0 | 2.55 - 5.6 | 2.55 | In |
Put | RXRX250124P00012000 | 0 | 12.0 | 3.7 - 8.0 | 3.7 | In |
Put | RXRX250124P00011500 | 0 | 11.5 | 3.3 - 7.5 | 3.3 | In |
Put | RXRX250124P00011000 | 0 | 11.0 | 3.0 - 7.0 | 3.0 | In |
Put | RXRX250124P00010500 | 0 | 10.5 | 2.7 - 6.5 | 2.7 | In |
Put | RXRX250124P00014000 | 0 | 14.0 | 5.9 - 10.0 | 5.9 | In |
Put | RXRX250124P00013500 | 0 | 13.5 | 5.4 - 9.5 | 5.4 | In |
Put | RXRX250124P00013000 | 0 | 13.0 | 5.2 - 9.0 | 5.2 | In |
Put | RXRX250124P00012500 | 0 | 12.5 | 4.6 - 8.5 | 4.6 | In |
Put | RXRX250124P00015000 | 0 | 15.0 | 7.5 - 11.0 | 7.5 | In |
Recursion Total Stockholder Equity
Total Stockholder Equity |
|
Recursion Pharmaceuticals Corporate Management
Christopher Gibson | CEO CoFounder | Profile | |
Kevin Leggat | Vice Accounting | Profile | |
Janelle Gordon | Vice Operations | Profile | |
Shafique MD | Interim Officer | Profile | |
Nathan Hatfield | Chief Officer | Profile |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.